Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : LIV-2008
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Henlius
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Henlius Has Reached an Exclusive License Agreement with Chiome for Antibodies Targeting Human TROP2
Details : Chiome agreed to grant Henlius an exclusive right and license to antibodies targeting human TROP2 and related intellectual property rights to research, develop, manufacture and commercialize the Licensed Products in China.
Brand Name : LIV-2008
Molecule Type : Large molecule
Upfront Cash : Undisclosed
January 14, 2021
Lead Product(s) : LIV-2008
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Henlius
Deal Size : Undisclosed
Deal Type : Licensing Agreement
LOOKING FOR A SUPPLIER?